Stifel analyst David Grossman lowered the firm’s price target on DocGo (DCGO) to $4 from $5.50 and keeps a Buy rating on the shares. Q1 revenue and non-GAAP EBITDA missed expectations and the company “materially lowered” 2025 guidance, notes the analyst, who points out that the revised range fell “well below” the firm’s estimates even though they were “significantly below consensus.”
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCGO:
- Qualcomm initiated, Lyft upgraded: Wall Street’s top analyst calls
- DocGo downgraded to Neutral from Buy at BTIG
- DocGo: Buy Rating Affirmed Amid Temporary Government Sector Challenges and Promising Growth in Other Segments
- DocGo Inc. Reports Q1 2025 Earnings Amid Strategic Shift
- DocGo reports Q1 EPS (9c) consensus 3c